Potential tariff on pharma imports into the US, while still under Section 232 investigation, is unlikely to impact the credit profiles of Indian pharma companies, India Ratings and Research (Ind-Ra) said.While the US contributes around 35% to the total revenue for leading domestic pharma companies, this proportion has been steadily declining over the past few years due to price erosion …
Read More »